Necessities · Markets · New Zealand

Why New Zealand.

6 min read NZ

The window

New Zealand. In-flight regulations by year.

2024 0 2025 0 2026 0 2027 0 2028 2 2029 0 2030 0 Peak crystallisation 2028. 2 regulations

Each bar counts effective dates in New Zealand between 2024 and 2030.

Source: hmm Ventures regulatory dataset.

The Necessity Doctrine, Chapter 6

New Zealand is the doctrine’s capital-efficiency case. The smallest market in the portfolio by GDP, population, venture deployment, and domestic addressable market. That is the risk. It is also why entry valuations are lower and the capital-efficiency test is sharper.

The country’s R&D and grant ecosystem (Callaghan Innovation transitioning to MBIE Innovation Services, NZGCP, the R&D Tax Incentive) plays a smaller-scale version of the Australian capital-efficiency role. The regulatory perimeter is concentrated in three Necessity-aligned domains: agritech and food security, biomedical, and renewable energy. Companies that build at the intersection of these and the international export channel have the Necessities-aligned profile that is harder to replicate in larger jurisdictions.

New Zealand, current state

  • Callaghan Innovation transition: functions transitioning from Callaghan Innovation to MBIE Innovation Services through 2025-2026.1
  • R&D Tax Incentive: 15% credit on eligible R&D expenditure between NZ$50K and NZ$120M; refundable for some early-stage entities.2
  • NZGCP Aspire NZ Seed Fund and Elevate NZ Venture Fund: active co-investment vehicles covering seed and Series A.3
  • Grant-funded regulated share: the majority of grant-funded NZ technology companies sit in T1 or T2 sectors, against a lower share in unfunded peers (author’s analysis, requires independent verification).

Capital efficiency: smallest inputs, persistent structural advantage

The NZ seed cheque is smaller than the AU equivalent. The seed valuation is lower than the SG equivalent. The runway is shorter than the JP equivalent. None of those is a feature in isolation. Together they reduce the capital required to build a valuable regulatory asset.

A T1 medtech company in Auckland that books TGA approval and FDA 510(k) clearance can build a regulatory asset that travels internationally, even if the company was formed in a smaller market. The difference is the cost of building it. Auckland engineering and clinical talent costs less, the Callaghan/MBIE grant ecosystem subsidises early R&D, and the seed entry valuation reflects the smaller domestic market rather than the international optionality.

The implication is that the regulatory asset, once built, can have export value that is not proportional to the size of the domestic market. The capital required to build it is smaller.

The grant-funded regulated share

New Zealand’s R&D ecosystem is grant-led to a degree no other comparable economy matches. Callaghan Innovation, before its transition, distributed material annual funding across direct grants, R&D project funding, and the R&D Tax Incentive process.4 MBIE Innovation Services is now absorbing those functions through 2025-2026.

The relevant figure for the doctrine is the regulated share of that grant funding. Internal analysis suggests a majority of relevant grant-funded technology companies sit in T1 or T2 categories: agritech, medtech, renewable energy, environmental monitoring, food traceability. The grants are not directed at regulation; they happen to flow disproportionately to companies whose product touches regulatory perimeters because those are the companies New Zealand industrial policy supports. This requires independent verification before being used as an external proof point.

That alignment is not accidental. The country’s economic specialisation in primary production, biomedical research, and clean energy aligns with three of the Five Necessities. The grant ecosystem appears to subsidise many companies operating near T1 and T2 regulatory perimeters.

Concentrated regulatory architecture

The country’s regulatory architecture is narrower and deeper than larger economies’. Three Necessity-aligned domains are mature; the rest are thinner.

Agritech and food security: Ministry for Primary Industries; AsureQuality verification; Food Act 2014 compliance regime; Country of Origin labelling; recent Food Standards Code updates aligning with FSANZ. Companies that ship dairy, meat, horticulture, or aquaculture into export markets sit inside a verification pathway that is internationally recognised.

Biomedical and medtech: Medsafe approval; Health and Disability Services Standards; SoMD framework aligning with TGA. The medtech export channel through Australia and onward to Asia and North America is established and well-trodden.

Renewable energy: Electricity Authority code; Climate Change Response Act emissions trading scheme; Emissions Reduction Plan; renewable generation deployment policy. The country runs a very high share of renewable electricity generation, which makes it a natural test bed for grid-edge technologies that export back into larger grid markets.

Adjacent verticals (financial services, consumer software, advertising technology) lack the same depth and the same grant alignment.

NZGCP and the public co-investment layer

New Zealand Growth Capital Partners (NZGCP) operates two vehicles that intersect with the seed and early venture market: the Aspire NZ Seed Fund and the Elevate NZ Venture Fund.3 Aspire co-invests with private investors at the seed stage on a matched-funding basis. Elevate co-invests with venture funds at Series A and later.

The structural feature is the matched-funding mandate. NZGCP capital follows private capital. A seed-stage T1 company that has cleared a Callaghan/MBIE grant gate and a private seed round has a clear path to Aspire matching. The company has effectively three sources of seed capital (grant, private, NZGCP) before Series A.

The implication is that the NZ seed company’s runway is composed differently from the Australian or Singaporean equivalent. More of the early capital is non-dilutive or matched, which compounds the capital-efficiency arithmetic.

Risks

The domestic addressable market is too small to support a Series A from domestic revenue alone. Every NZ T1 or T2 Necessities is an export Necessities from incorporation. Companies that delay the export build until post-Series A face structural exit risk.

The country’s tax law on equity investing is unsettled. Section CB 4 of the Income Tax Act 2007 contains revenue-account characterisation provisions whose application to venture exits is not always certain.5 Foreign-domiciled funds investing into NZ companies need explicit tax counsel and structuring at fund formation. The risk is real but quantifiable.

Failure rates are higher than the other three markets. The doctrine accepts the higher base rate because the entry valuations are lower and the regulatory asset, when built, has equivalent export value. The arithmetic remains favourable on a portfolio basis if the failure-rate premium is priced into entry.

The MBIE transition itself is a near-term risk. Functional handover between agencies has historically introduced delays in grant disbursement and continuity-of-relationship risk for companies mid-programme. The transition window is the period to monitor.

What the doctrine produces in NZ

A small number of well-priced companies. T1 medtech with Medsafe and TGA in hand and FDA 510(k) on roadmap. T2 agritech selling into MPI-regulated processors with cross-listed export to Australian and U.S. food businesses. T1 grid-edge technology trialling under Electricity Authority sandbox provisions and licensing into larger grid markets.

The pool is small. The selection bar is high. The capital required to participate is the smallest of the four markets. The next chapter examines Singapore, where the friction is lowest and the regional foothold is the structural feature.

Chapter 7 examines Singapore: the regional foothold, the regulatory sandbox, and the function it serves in a four-market portfolio.

Footnotes

  1. New Zealand Ministry of Business, Innovation and Employment, Innovation Services transition announcement, 2025. Operational handover from Callaghan Innovation continuing through 2026. ↩

  2. Inland Revenue New Zealand, R&D Tax Incentive overview, current parameters. ↩

  3. New Zealand Growth Capital Partners, Aspire NZ Seed Fund and Elevate NZ Venture Fund disclosures, 2025. ↩ ↩2

  4. Callaghan Innovation Annual Reports through FY24. Distribution figures aggregate direct grants and R&D Tax Incentive administration; precise figures vary by year and require independent verification against the official annual report series. ↩

  5. Income Tax Act 2007 (NZ), section CB 4. Revenue-account characterisation for shares acquired with a purpose of disposal. ↩